Population Pharmacokinetics — MCQs
The therapeutic index of a drug is defined as the ratio between the toxic dose and the effective dose.
What is the mechanism of metabolism for alcohol, aspirin, and phenytoin at high doses?
What is the 95% confidence interval for the intraocular pressure (IOP) in the 400 people, given a mean of 25 mm Hg and a standard deviation of 10 mm Hg?
In which phase of clinical trials is drug dosing typically determined?
Which of the following statements about phase IV clinical trials is correct?
Lidocaine is used in a loading dose for the treatment of arrhythmias. The loading dose of this drug depends upon which of the following factors?
Match the following drugs in Column A with their contraindications in Column B. | Column A | Column B | | :-- | :-- | | 1. Morphine | 1. QT prolongation | | 2. Amiodarone | 2. Thromboembolism | | 3. Vigabatrin | 3. Pregnancy | | 4. Estrogen preparations | 4. Head injury |
Low apparent volume of distribution of drug indicates that:
The following plot comparing pharmacokinetics of different ibuprofen brands is called:
Which calcium channel blocker has the shortest duration of action?
Population Pharmacokinetics Indian Medical PG Practice Questions and MCQs
Question 1: The therapeutic index of a drug is defined as the ratio between the toxic dose and the effective dose.
- A. Margin of safety
- B. Ratio of toxic dose to effective dose (Correct Answer)
- C. Efficacy of the drug
- D. Drug potency
Explanation: ***Ratio of toxic dose to effective dose***- The **therapeutic index (TI)** is quantitatively defined as the ratio of the toxic dose (TD50 or LD50) to the effective dose (ED50) [1, 2].- This ratio provides a measure of **drug safety**, indicating the range between the therapeutic and toxic concentrations [1, 3].*Margin of safety*- While related to safety, the **margin of safety** is a different concept, often calculated as (TD1 - ED99) / ED99, focusing on the overlap between very few people experiencing toxicity and almost everyone receiving benefit [2].- The therapeutic index is a broader, simpler ratio that doesn't explicitly guarantee overlap safety but indicates overall drug risk.*Efficacy of the drug*- **Efficacy** refers to the maximal effect a drug can produce regardless of the dose, and it is independent of the therapeutic index [2].- A drug can have high efficacy but a narrow therapeutic index, meaning it is very effective but also very toxic at doses slightly above the therapeutic range.*Drug potency*- **Potency** is the amount of drug needed to produce a given effect (e.g., ED50), reflecting its affinity for receptors and efficiency of action [2].- It is distinct from the therapeutic index, which assesses the separation between desired and undesired effects, not the concentration required to achieve a therapeutic effect.
Question 2: What is the mechanism of metabolism for alcohol, aspirin, and phenytoin at high doses?
- A. First pass kinetics
- B. First order kinetics
- C. Zero order kinetics (Correct Answer)
- D. Second order kinetics
Explanation: ***Zero order kinetics*** - This mechanism occurs when the **metabolic enzymes become saturated at high drug concentrations**, leading to a constant amount (not a constant percentage) of drug being eliminated per unit time. - Alcohol, aspirin, and phenytoin are examples of drugs that exhibit **saturable metabolism**, transitioning from first-order to zero-order kinetics at higher doses. *First pass kinetics* - This describes the **metabolism of a drug by the liver or gut wall enzymes before it reaches systemic circulation** after oral administration. - While relevant to the oral bioavailability of these drugs, it does not describe the specific mechanism of elimination at high doses. *First order kinetics* - In this mechanism, a **constant fraction or percentage of the drug is eliminated per unit of time**, meaning the rate of elimination is directly proportional to the drug concentration. - Most drugs follow first-order kinetics at therapeutic doses because metabolizing enzymes are not saturated. *Second order kinetics* - This is a **less common pharmacokinetic model** where the rate of elimination is proportional to the square of the drug concentration or involves two reactants. - It does not typically describe the common elimination patterns of most drugs, including alcohol, aspirin, and phenytoin.
Question 3: What is the 95% confidence interval for the intraocular pressure (IOP) in the 400 people, given a mean of 25 mm Hg and a standard deviation of 10 mm Hg?
- A. 22-28
- B. 23-27
- C. 21-29
- D. 24-26 (Correct Answer)
Explanation: ***24-26*** - This is the correct 95% confidence interval calculated using the formula: **mean ± (Z-score × standard error of the mean)**. - For a 95% confidence interval, the **Z-score is 1.96**. - The **standard error of the mean (SEM)** = standard deviation / √(sample size) = 10 / √400 = 10 / 20 = **0.5**. - Therefore: 25 ± (1.96 × 0.5) = 25 ± 0.98 = **24.02 to 25.98**, which rounds to **24-26**. *22-28* - This interval is too wide for a 95% confidence interval with the given parameters. - An interval of ±3 would correspond to a Z-score of 3/0.5 = 6, which is far beyond the **1.96 required for 95% confidence**. - This would represent a much higher confidence level (>99.9%). *23-27* - This interval is slightly too wide, implying a larger margin of error than calculated. - A range of ±2 would require a Z-score of 2/0.5 = 4 times the SEM, which **overestimates the 95% confidence interval**. - This would correspond to approximately 99.99% confidence. *21-29* - This interval is significantly too wide for a 95% confidence interval. - An interval of ±4 would require a Z-score of 4/0.5 = 8 times the SEM, which would correspond to an **extremely high confidence level** (virtually 100%). - This dramatically exceeds what is needed for 95% confidence.
Question 4: In which phase of clinical trials is drug dosing typically determined?
- A. Phase 1 (Correct Answer)
- B. Phase 2
- C. Phase 3
- D. Phase 4
- E. Phase 0
Explanation: ***Phase 1*** - This phase involves a small group of **healthy volunteers** to assess the drug's safety, **pharmacokinetics (PK)**, and establish an initial dosing range. - The primary goal is to determine a **safe dosage level**, establish the **maximum tolerated dose (MTD)**, and identify potential side effects. - This is where drug dosing is **typically determined**. *Phase 0* - This is an exploratory phase involving **microdosing** studies with subtherapeutic doses. - The goal is to gather preliminary PK/PD data, but **not to determine therapeutic dosing**. *Phase 2* - This phase involves a larger group of **patients** with the condition to be treated. - The main goal is to evaluate the drug's **effectiveness** and further assess safety, but not primarily to determine initial dosing. *Phase 3* - This phase involves a large number of patients across multiple sites to confirm the drug's **efficacy** and monitor side effects in a broader population. - Dosing strategies have generally been established in earlier phases, and this phase primarily validates them. *Phase 4* - This phase occurs **after a drug has been approved** and marketed. - It involves ongoing surveillance to monitor long-term effects, collect additional information on safety, and identify new uses, but not initial dose determination.
Question 5: Which of the following statements about phase IV clinical trials is correct?
- A. It is primarily focused on the efficacy of the drug.
- B. It involves monitoring the long-term effects and safety of drugs. (Correct Answer)
- C. It is conducted before a drug is submitted for approval.
- D. It focuses primarily on determining the optimal dosage for patients.
Explanation: ***It involves monitoring the long-term effects and safety of drugs.*** - **Phase IV clinical trials** are conducted **after a drug has been approved and marketed** to monitor its performance in the general population. - The primary goals include assessing the **long-term safety profile**, identifying rare adverse effects, and evaluating effectiveness under real-world conditions. *It is primarily focused on the efficacy of the drug.* - The primary focus on **drug efficacy** is typically addressed in **Phase II and Phase III clinical trials**, where controlled studies evaluate if the drug works as intended. - While efficacy is re-evaluated in real-world settings during Phase IV, it's not the primary or exclusive focus, which broadens to safety and comparative effectiveness. *It is conducted before a drug is submitted for approval.* - Trials conducted **before drug submission for approval** are typically **Phase I, Phase II, and Phase III clinical trials**, which are designed to establish safety, dosage, and initial efficacy. - **Phase IV trials** specifically begin **after a drug has received regulatory approval** and is available to the public. *It focuses primarily on determining the optimal dosage for patients.* - **Optimal dosage determination** is largely the domain of **Phase I and Phase II clinical trials**, where escalating doses are tested in small groups to identify a safe and effective range. - Phase IV studies might explore different dosing regimens in specific patient populations, but they do not primarily determine initial optimal dosing.
Question 6: Lidocaine is used in a loading dose for the treatment of arrhythmias. The loading dose of this drug depends upon which of the following factors?
- A. Clearance
- B. Volume of distribution (Correct Answer)
- C. Half-life
- D. Bioavailability
- E. Elimination rate constant
Explanation: ***Volume of distribution*** - The **loading dose** of a drug is primarily determined by its **volume of distribution (Vd)** and the **target plasma concentration**. - A larger **Vd** means the drug distributes widely into tissues, requiring a larger loading dose to achieve the desired concentration in the central compartment. *Clearance* - **Clearance** dictates the **maintenance dose** needed to sustain a steady-state concentration once the loading dose has been administered. - It reflects the rate at which the drug is eliminated from the body, not how much is initially needed to fill the distribution volume. *Half-life* - **Half-life** determines the **time required to reach steady-state** and the **dosing interval** for maintaining therapeutic concentrations. - While related to clearance and Vd, it does not directly determine the magnitude of the initial loading dose itself. *Bioavailability* - **Bioavailability** is the fraction of administered drug that reaches the systemic circulation in an unchanged form. - It influences the oral dose required to achieve a certain plasma concentration, but the concept of loading dose is typically considered for the intravenous route where bioavailability is 100%. *Elimination rate constant* - The **elimination rate constant (ke)** describes the rate of drug elimination and is related to clearance and volume of distribution (ke = Cl/Vd). - Like clearance, it determines the **maintenance dose** and dosing frequency, not the initial loading dose required to achieve therapeutic levels.
Question 7: Match the following drugs in Column A with their contraindications in Column B. | Column A | Column B | | :-- | :-- | | 1. Morphine | 1. QT prolongation | | 2. Amiodarone | 2. Thromboembolism | | 3. Vigabatrin | 3. Pregnancy | | 4. Estrogen preparations | 4. Head injury |
- A. A-1, B-3, C-2, D-4
- B. A-4, B-1, C-3, D-2 (Correct Answer)
- C. A-3, B-2, C-4, D-1
- D. A-2, B-4, C-1, D-3
Explanation: ***A-4, B-1, C-3, D-2*** - **Morphine** is contraindicated in **head injury** as it can increase intracranial pressure and mask neurological symptoms. - **Amiodarone** is contraindicated in patients with **QT prolongation** due to its risk of inducing more severe arrhythmias like Torsades de Pointes. - **Vigabatrin** is contraindicated during **pregnancy** due to its potential for teratogenicity and adverse effects on fetal development. - **Estrogen preparations** are contraindicated in patients with a history of **thromboembolism** due to their increased risk of blood clot formation. *A-1, B-3, C-2, D-4* - This option incorrectly matches **Morphine** with QT prolongation and **Estrogen preparations** with head injury, which are not their primary contraindications. - It also incorrectly links **Vigabatrin** with thromboembolism and **Amiodarone** with pregnancy. *A-3, B-2, C-4, D-1* - This choice incorrectly associates **Morphine** with pregnancy and **Vigabatrin** with head injury, which are not the most critical or direct contraindications. - It also misaligns **Amiodarone** with thromboembolism and **Estrogen preparations** with QT prolongation. *A-2, B-4, C-1, D-3* - This option incorrectly matches **Morphine** with thromboembolism and **Amiodarone** with head injury, which are not their most significant contraindications. - It also incorrectly links **Vigabatrin** with QT prolongation and **Estrogen preparations** with pregnancy.
Question 8: Low apparent volume of distribution of drug indicates that:
- A. Drug has low bioavailability
- B. Drug has low efficacy
- C. Drug is not extensively distributed to tissue (Correct Answer)
- D. Drug has low half life
Explanation: ***Drug is not extensively distributed to tissue*** - A **low apparent volume of distribution (Vd)** suggests that the drug primarily remains in the **vascular compartment**. - This indicates **minimal binding to peripheral tissues** and less distribution into extravascular spaces. *Drug has low bioavailability* - **Bioavailability** refers to the fraction of an administered drug that reaches the **systemic circulation unchanged**. - While related to drug disposition, a low Vd does not directly imply low bioavailability; a drug can have high bioavailability but remain largely in the blood. *Drug has low efficacy* - **Efficacy** is the maximum effect a drug can produce regardless of the dose. - Vd relates to drug distribution, not its pharmacological effect or **intrinsic activity** at its target. *Drug has low half life* - The **half-life** of a drug is determined by its **volume of distribution (Vd)** and **clearance (CL)** (t½ = 0.693 × Vd / CL). - While a low Vd can contribute to a shorter half-life if clearance is high, Vd alone does not solely determine half-life; clearance also plays a significant role.
Question 9: The following plot comparing pharmacokinetics of different ibuprofen brands is called:
- A. Kaplan Meier plot
- B. Spaghetti plot (Correct Answer)
- C. Funnel plot
- D. Forest plot
Explanation: ***Spaghetti plot*** - A **spaghetti plot** is characterized by multiple lines, each representing an individual's data across different time points or conditions, creating a visual resemblance to strands of spaghetti. This plot is ideal for visualizing **individual changes** and patterns in longitudinal data. - In pharmacokinetics, spaghetti plots are useful to compare the **drug concentration profiles** of different brands or formulations within individuals or across a group, showing individual variability. *Kaplan Meier plot* - A Kaplan-Meier plot (or survival curve) is used to estimate the **survival probability** over time for a group of individuals. - It displays a step-wise curve that decreases over time, representing the proportion of subjects **surviving** or remaining event-free, which is clearly not what is depicted in the image. *Funnel plot* - A **funnel plot** is a scatter plot used in meta-analyses to detect **publication bias** or small study effects. - It plots the study effect size against a measure of its precision (e.g., standard error), typically forming a triangular or funnel shape if no bias is present. *Forest plot* - A **forest plot** is a graphical display used in meta-analyses to illustrate the **results of individual studies** along with their pooled estimate. - Each study is represented by a square and a horizontal line indicating the effect size and its **confidence interval**, respectively.
Question 10: Which calcium channel blocker has the shortest duration of action?
- A. Diltiazem
- B. Amlodipine
- C. Nimodipine (Correct Answer)
- D. Verapamil
Explanation: ***Nimodipine*** - Nimodipine is a **dihydropyridine calcium channel blocker** specifically formulated for cerebral vasodilation and used in conditions like **subarachnoid hemorrhage**. - It has a relatively **short half-life** and rapid onset, making its duration of action shorter compared to other commonly used calcium channel blockers. *Amlodipine* - Amlodipine is known for its **long duration of action** and once-daily dosing due to its slow absorption and high bioavailability. - Its prolonged action is beneficial for conditions like **hypertension and angina**, where sustained vasodilation is desired. *Diltiazem* - Diltiazem's duration of action is **intermediate** compared to other calcium channel blockers, often requiring BID to TID dosing for immediate-release formulations. - It's a **non-dihydropyridine calcium channel blocker** with effects on both vascular smooth muscle and cardiac conduction. *Verapamil* - Verapamil also has an **intermediate duration of action**, similar to diltiazem, with immediate-release forms requiring multiple daily doses. - As a **non-dihydropyridine calcium channel blocker**, it has significant effects on myocardial contractility and AV nodal conduction.
Want unlimited practice?
Get full access to all questions, explanations, and performance tracking.
Start For Free